Results 131 to 140 of about 329,542 (317)

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

Hepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger, Holly E. Holmes, Tina Hu‐Seliger, Rodney W. Butt, Stephen A. Harrison, Dariush Mozaffarian, Oliver Chen, Leonard Guarente   +7 more
wiley   +1 more source

Early thrombolysis combined with anticoagulation and antibiotics for acute portal venous system thrombosis secondary to intra-abdominal infection

Archives of Medical Science, 2023
Fangbo Gao, Ran Wang, Longfei Han, Rui Zhang, Xingshun Qi   +4 more
doaj   +1 more source

Pharmacological Consequences of Liver Cirrhosis

, 2023
In recent years, the traditional idea of cirrhotic patients being auto-anticoagulated due to the decreased synthesis of coagulation proteins has been reexamined.
Kinebuchi, Dai Alexander
core  

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, EarlyView.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Hepatology, EarlyView., 2022
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley   +17 more
wiley   +1 more source

Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis

Gastroenterology Research and Practice, 2019
Objective. The diagnostic value of antinuclear antibodies (ANAs) including anti-gp210 and anti-sp100 for primary biliary cholangitis/cirrhosis (PBC) has been widely reported.
Qian Zhang, Zhiqiang Liu, Shanshan Wu, Weijia Duan, Sha Chen, Xiaojuan Ou, Hong You, Yuanyuan Kong, Jidong Jia   +8 more
doaj   +1 more source

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) is a potent, pan‐genotypic inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. Its antiviral activity was evaluated in an ascending dose phase I clinical trial involving 30 patients treated once a day for 7 days. After treatment initiation, plasma HCV RNA declined in a biphasic manner with a mean reduction of 2.3 log10 ...
Carolin Zitzmann, Ruy M. Ribeiro, Aurélien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

CD11b+CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen–liver axis

Hepatology, EarlyView., 2022
A population of splenic monocytes migrate into the liver and shift to macrophages, which account for the exacerbation of liver fibrosis. Abstract Background and Aims Monocyte‐derived macrophages (MoMFs), a dominant population of hepatic macrophages under inflammation, play a crucial role in liver fibrosis progression.
Shaoying Zhang, Dan Wan, Mengchen Zhu, Guihu Wang, Xurui Zhang, Na Huang, Jian Zhang, Chongyu Zhang, Qi Shang, Chen Zhang, Xi Liu, Fanfan Liang, Chunyan Zhang, Guangyao Kong, Jing Geng, Libo Yao, Shemin Lu, Yongyan Chen, Zongfang Li   +18 more
wiley   +1 more source